首页> 外文期刊>Journal of biomedicine & biotechnology >Efficacy and Cytokine Modulating Effects of Tacrolimus in Systemic Lupus Erythematosus: A Review
【24h】

Efficacy and Cytokine Modulating Effects of Tacrolimus in Systemic Lupus Erythematosus: A Review

机译:他克莫司对系统性红斑狼疮的疗效及细胞因子调节作用的研究进展

获取原文
获取原文并翻译 | 示例
       

摘要

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease with involvement of both B cells and cytotoxic T lymphocytes and several cytokines aberrations. Standard therapy for SLE has its limitations. Tacrolimus, a novel calcineurin inhibitor with potent immunosuppressive effects, has been shown in the recent years to be effective in SLE therapy. This paper serves to collate the experimental and clinical data on the efficacy of tacrolimus in the treatment of SLE and lupus nephritis. Tacrolimus as a key component of multitarget therapy in SLE is also discussed. The immunocytokine modulatory effects of tacrolimus are also reviewed with reference to SLE. It can be concluded that tacrolimus has an established role in the management of SLE.
机译:系统性红斑狼疮(SLE)是一种复杂的系统性自身免疫病,涉及B细胞和细胞毒性T淋巴细胞,并伴有多种细胞因子异常。 SLE的标准疗法有其局限性。他克莫司是一种新型的钙调神经磷酸酶抑制剂,具有有效的免疫抑制作用,近年来已显示出对SLE治疗有效。本文用于整理他克莫司治疗SLE和狼疮性肾炎的实验和临床数据。还讨论了他克莫司作为SLE多靶点治疗的关键组成部分。他克莫司的免疫细胞因子调节作用也参考SLE进行了综述。可以得出结论,他克莫司在SLE的治疗中具有确定的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号